Plasminogen activators - Pipeline Insight, 2022
This report can be delivered to the clients within 48 hours
DelveInsight’s, “Plasminogen activators - Pipeline Insight, 2022” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Plasminogen activators pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Plasminogen activators: Overview
Plasmin is the serine protease responsible for degradation of fibrin. Two forms of the zymogen precursor plasminogen circulate in plasma, the native more abundant form, Glu-plasminogen, and the intermediate form Lys-plasminogen, formed by cleavage of the N-terminal peptide from Glu-plasminogen. The plasminogen activator (PA) system is an extracellular proteolytic enzyme system associated with various physiological and pathophysiological processes. The first-generation plasminogen activators like streptokinase and urokinase are compounds found in nature that lack fibrin selectivity, while second-generation activators including t-PA and scu-PA are natural human proteins that possess some fibrin selectivity and can be produced either by selected human cell cultures or by recombinant DNA methods. The third-generation plasminogen activators are numerous compounds that are in clinical development and possess enhanced properties as a result either of chemical modification or of the application of recombinant DNA technology.
Report Highlights
This segment of the Plasminogen activators report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Plasminogen activators Emerging Drugs
Further product details are provided in the report……..
Plasminogen activators: Therapeutic Assessment
This segment of the report provides insights about the different Plasminogen activators drugs segregated based on following parameters that define the scope of the report, such as:
Plasminogen activators: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Plasminogen activators therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Plasminogen activators drugs.
Plasminogen activators Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Plasminogen activators - Pipeline Insight, 2022” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Plasminogen activators pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Plasminogen activators: Overview
Plasmin is the serine protease responsible for degradation of fibrin. Two forms of the zymogen precursor plasminogen circulate in plasma, the native more abundant form, Glu-plasminogen, and the intermediate form Lys-plasminogen, formed by cleavage of the N-terminal peptide from Glu-plasminogen. The plasminogen activator (PA) system is an extracellular proteolytic enzyme system associated with various physiological and pathophysiological processes. The first-generation plasminogen activators like streptokinase and urokinase are compounds found in nature that lack fibrin selectivity, while second-generation activators including t-PA and scu-PA are natural human proteins that possess some fibrin selectivity and can be produced either by selected human cell cultures or by recombinant DNA methods. The third-generation plasminogen activators are numerous compounds that are in clinical development and possess enhanced properties as a result either of chemical modification or of the application of recombinant DNA technology.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Plasminogen activators R&D. The therapies under development are focused on novel approaches for Plasminogen activators.
This segment of the Plasminogen activators report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Plasminogen activators Emerging Drugs
- TMS-007: TMS
- Recombinant staphylokinase: Supergene
Further product details are provided in the report……..
Plasminogen activators: Therapeutic Assessment
This segment of the report provides insights about the different Plasminogen activators drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Plasminogen activators
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Plasminogen activators: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Plasminogen activators therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Plasminogen activators drugs.
Plasminogen activators Report Insights
- Plasminogen activators Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Plasminogen activators drugs?
- How many Plasminogen activators drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Plasminogen activators?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Plasminogen activators therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Plasminogen activators and their status?
- What are the key designations that have been granted to the emerging drugs?
- Genentech
- TMS
- Tasly Pharmaceutical
- Cereno Scientific
- Supergene
- Boehringer Ingelheim
- Chiesi Farmaceutici
- Tenecteplase
- TMS 007
- Prourokinase recombinant
- CS-1
- Recombinant staphylokinase
- Alteplase
- CUSA-081
Introduction
Executive Summary
Plasminogen activators: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Plasminogen activators – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Plasminogen activators companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Plasminogen activators Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Recombinant staphylokinase: Supergene
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
TMS 007: TMS
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
CS-1: Cereno Scientific
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Plasminogen activators Key Companies
Plasminogen activators Key Products
Plasminogen activators- Unmet Needs
Plasminogen activators- Market Drivers and Barriers
Plasminogen activators- Future Perspectives and Conclusion
Plasminogen activators Analyst Views
Plasminogen activators Key Companies
Appendix
Executive Summary
Plasminogen activators: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Plasminogen activators – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Plasminogen activators companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Plasminogen activators Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Recombinant staphylokinase: Supergene
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
TMS 007: TMS
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
CS-1: Cereno Scientific
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Plasminogen activators Key Companies
Plasminogen activators Key Products
Plasminogen activators- Unmet Needs
Plasminogen activators- Market Drivers and Barriers
Plasminogen activators- Future Perspectives and Conclusion
Plasminogen activators Analyst Views
Plasminogen activators Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Plasminogen activators
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Plasminogen activators
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Plasminogen activators
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Plasminogen activators
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
